Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

Abstract

The advent of novel immunotherapy and tyrosine kinase inhibitors has ushered a new era in the treatment of Hodgkin and non-Hodgkin lymphomas. Allogeneic hematopoietic cell transplantation remains, however, a vital component in the management and potential cure of lymphomas, especially in the relapsed setting. Considering the biological and clinical heterogeneity of various subtypes of lymphomas, the optimal intensity of conditioning regimens remains controversial. Reduced intensity conditioning regimens have broadened applicability of the procedure to older and frail patients. Observational studies suggest that although reduced intensity allografting is associated with higher risk of relapse, overall survival is comparable and in some cases even better, than observed with myeloablative regimens. Here, we review the available published data pertaining to allogeneic hematopoietic cell transplantation using reduced intensity or myeloablative conditioning for various lymphoma histologies. Owing to the lack of randomized prospective trials, recommendations are mainly based on registry and single-institution studies. Special emphasis must be given to implementing strategies to prevent relapse when using reduced intensity regimens. Identifying particular patients who may benefit from myeloablative regimens in lymphomas remains to be better defined.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101–6108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684.

    Article  CAS  PubMed  Google Scholar 

  4. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093–3099.

    Article  CAS  PubMed  Google Scholar 

  5. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479.

    Article  CAS  PubMed  Google Scholar 

  6. Reimer P, Schertlin T, Rudiger T, Geissinger E, Roth S, Kunzmann V et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5: 304–311.

    Article  CAS  PubMed  Google Scholar 

  7. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  8. Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012; 18: 788–793.

    Article  PubMed  Google Scholar 

  9. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.

    Article  CAS  PubMed  Google Scholar 

  10. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462.

    Article  CAS  PubMed  Google Scholar 

  12. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.

  13. Gribben JG . How I treat indolent lymphoma. Blood 2007; 109: 4617–4626.

    Article  CAS  PubMed  Google Scholar 

  14. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK . Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019–5026.

    Article  PubMed  Google Scholar 

  15. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832–1836.

    CAS  PubMed  Google Scholar 

  16. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530–5536.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695–3700.

    Article  PubMed  Google Scholar 

  18. Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Diez-Martin JL et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95: 1176–1182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211–217.

    Article  PubMed  Google Scholar 

  20. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T et al. Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a phase two multicenter trial from the blood and marrow transplant clinical trials network. Biol Blood Marrow Transplant 2016; 22: 1440–1448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Klyuchnikov E, Bacher U, Kroger NM, Hari PN, Ahn KW, Carreras J et al. Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors. Biol Blood Marrow Transplant 2015; 21: 2091–2099.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236–245.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti GJ et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009; 147: 719–728.

    Article  PubMed  Google Scholar 

  24. Laport GG . Changing role of stem cell transplantation in follicular lymphoma. Hematology Am Soc Hematol Educ Program 2012; 2012: 417–425.

    Article  PubMed  Google Scholar 

  25. Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M . Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Bone Marrow Transplant 2013; 48: 1489–1496.

    Article  CAS  PubMed  Google Scholar 

  26. Dreyling M, Hiddemann W, European MCLN. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009, 542–551.

    Article  Google Scholar 

  27. Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795.

    Article  CAS  PubMed  Google Scholar 

  28. Fisher RI . Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol 1996; 7: S35–S39.

    Article  PubMed  Google Scholar 

  29. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200–208.

    CAS  PubMed  Google Scholar 

  30. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511–518.

    Article  PubMed  Google Scholar 

  31. Weisenburger DD, Vose JM, Greiner TC, Lynch JC, Chan WC, Bierman PJ et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64: 190–196.

    Article  CAS  PubMed  Google Scholar 

  32. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355–362.

    Article  CAS  PubMed  Google Scholar 

  33. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 2014; 32: 273–281.

    Article  PubMed  Google Scholar 

  34. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2013; 19: 625–631.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ott G, Kalla J, Ott MM, Schryen B, Katzenberger T, Muller JG et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997; 89: 1421–1429.

    Article  CAS  PubMed  Google Scholar 

  36. Schaffel R, Hedvat CV, Teruya-Feldstein J, Persky D, Maragulia J, Lin D et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010; 21: 133–139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer cell 2003; 3: 185–197.

    Article  CAS  PubMed  Google Scholar 

  38. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630–2639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–565.

    Article  CAS  PubMed  Google Scholar 

  40. Geisler CH, Kolstad A, Laurell A, Raty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530–1533.

    Article  CAS  PubMed  Google Scholar 

  41. Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016; 127: 1559–1563.

    Article  CAS  PubMed  Google Scholar 

  42. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535–3542.

    Article  CAS  PubMed  Google Scholar 

  43. Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for blood and marrow transplantation. Biol Blood Marrow Transplant 2010; 16: 1419–1427.

    Article  PubMed  Google Scholar 

  44. Le Gouill S, Kroger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23: 2695–2703.

    Article  CAS  PubMed  Google Scholar 

  45. Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T et al. Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol 2014; 93: 1587–1597.

    Article  PubMed  Google Scholar 

  46. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 2016; 127: 938–947.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT et al. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer 2015; 121: 3709–3716.

    Article  CAS  PubMed  Google Scholar 

  48. Tessoulin B, Ceballos P, Chevallier P, Blaise D, Tournilhac O, Gauthier J et al. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant 2016; 51: 1184–1190.

    Article  CAS  PubMed  Google Scholar 

  49. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY et al. Allotransplantation for patients age >/=40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant 2014; 20: 960–968.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2014; 25: 1053–1058.

    Article  CAS  PubMed  Google Scholar 

  51. Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M et al. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncol 2016; 12: 2631–2642.

    Article  CAS  PubMed  Google Scholar 

  52. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008; 19: 1935–1940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143: 395–403.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012; 120: 4256–4262.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol 2016; 174: 235–248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342–1348.

    Article  PubMed  Google Scholar 

  57. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant 2013; 19: 746–753.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Robinson SP, Boumendil A, Finel H, Blaise D, Poire X, Nicolas-Virelizier E et al. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplant 2016; 51: 365–371.

    Article  CAS  PubMed  Google Scholar 

  59. Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014; 15: 757–766.

    Article  CAS  PubMed  Google Scholar 

  60. Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN . Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplant 2014; 49: 599–606.

    Article  CAS  PubMed  Google Scholar 

  61. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671–3677.

    Article  CAS  PubMed  Google Scholar 

  62. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572–578.

    Article  CAS  PubMed  Google Scholar 

  63. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  PubMed  Google Scholar 

  64. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993; 11: 2342–2350.

    Article  CAS  PubMed  Google Scholar 

  65. Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230–238.

    Article  PubMed  Google Scholar 

  66. Genadieva Stavrik SG, Boumendil A, Thomson K, Briones J, Corradini P, Bacigalupo A et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation in relapsed Hodgkin’s lymphoma in recent years. a retrospective analysis of the lymphoma working party of the European Group for Blood and Marrow Transplantation. Blood 2014; 124: 2562.

    Article  Google Scholar 

  67. Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 2060–2067.

    Article  CAS  PubMed  Google Scholar 

  68. Sabattini E, Bacci F, Sagramoso C, Pileri SA . WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010; 102: 83–87.

    CAS  PubMed  Google Scholar 

  69. Vose J, Armitage J, Weisenburger D . International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124–4130.

    Article  PubMed  Google Scholar 

  70. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31: 3100–3109.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176.

    Article  PubMed  Google Scholar 

  72. Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 561–567.

    Article  PubMed  Google Scholar 

  73. Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007; 40: 443–450.

    Article  CAS  PubMed  Google Scholar 

  74. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 2008; 14: 480–483.

    Article  PubMed  Google Scholar 

  75. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.

    Article  PubMed  Google Scholar 

  76. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951–3958.

    Article  PubMed  Google Scholar 

  77. Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011; 22: 1608–1613.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S . Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012; 47: 65–72.

    Article  CAS  PubMed  Google Scholar 

  79. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520–526.

    Article  CAS  PubMed  Google Scholar 

  80. Kim SW, Yoon SS, Suzuki R, Matsuno Y, Yi HG, Yoshida T et al. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia 2013; 27: 1394–1397.

    Article  CAS  PubMed  Google Scholar 

  81. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013; 19: 602–606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Czajczynska A, Gunther A, Repp R, Humpe A, Schub N, Raff T et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2013; 19: 1632–1637.

    Article  CAS  PubMed  Google Scholar 

  83. Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014; 28: 1885–1891.

    Article  CAS  PubMed  Google Scholar 

  84. Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2015; 26: 386–392.

    Article  CAS  PubMed  Google Scholar 

  85. Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 2012; 120: 1734–1741.

    Article  CAS  PubMed  Google Scholar 

  86. Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31: 1530–1538.

    Article  CAS  PubMed  Google Scholar 

  87. Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J et al. The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen. Biol Blood Marrow Transplant 2015; 21: 1746–1753.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 50–58.

    Article  PubMed  Google Scholar 

  89. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50: 1037–1056.

    Article  CAS  PubMed  Google Scholar 

  90. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21: 1863–1869.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Blaise D, Tabrizi R, Boher JM, Le Corroller-Soriano AG, Bay JO, Fegueux N et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer 2013; 119: 602–611.

    Article  CAS  PubMed  Google Scholar 

  92. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012; 119: 6373–6378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M A Kharfan-Dabaja.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kharfan-Dabaja, M., El-Jurdi, N., Ayala, E. et al. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?. Bone Marrow Transplant 52, 1487–1494 (2017). https://doi.org/10.1038/bmt.2017.55

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.55

This article is cited by

Search

Quick links